No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome

BACKGROUND/AIMS: This study evaluated the role of hypomethylating agents (HMA) compared to best supportive care (BSC) for patients with high or very-high (H/VH) risk myelodysplastic syndrome (MDS) according to the Revised International Prognostic Scoring System. METHODS: A total of 279 H/VH risk MDS...

Descripción completa

Detalles Bibliográficos
Autores principales: Sohn, Sang Kyun, Moon, Joon Ho, Lee, In Hee, Ahn, Jae Sook, Kim, Hyeoung Joon, Chung, Joo Seop, Shin, Ho Jin, Park, Sung Woo, Lee, Won Sik, Lee, Sang Min, Kim, Hawk, Lee, Ho Sup, Kim, Yang Soo, Cho, Yoon Young, Bae, Sung Hwa, Lee, Ji Hyun, Kim, Sung Hyun, Song, Ik Chan, Kwon, Ji Hyun, Lee, Yoo Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234402/
https://www.ncbi.nlm.nih.gov/pubmed/29232940
http://dx.doi.org/10.3904/kjim.2016.426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234402/
https://www.ncbi.nlm.nih.gov/pubmed/29232940
http://dx.doi.org/10.3904/kjim.2016.426

Ejemplares similares